Natural Disease Progression in Participants With Choroideremia
Completed
Conditions studied: Choroideremia
In brief
The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants. The secondary objectives are to describe demographic and baseline clinical characteristics among CHM participants and to match CHM participants in the Intelligent Research in Sight (IRIS®) Registry to Biogen's investigator sponsored trial (IST) study population using propensity score matching.
Key facts
- Study ID
- NCT04795206
- Run by
- Biogen
- People needed
- 1178
- Starts
- 2020-08-26
- Expected to finish
- 2021-08-10
- Last updated by the study team
- 2021-09-08
Who can join
Age: 10 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.